Trodelvy Disease Interactions

The safety of sacituzumab govitecan has not been established in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN]) or severe (total bilirubin greater than 3 x ULN) liver dysfunction; it has not been tested in patients with AST or ALT greater than 3 x ULN without liver metastases, or AST or ALT greater than 5 x ULN with liver metastases. No recommendations can be made for the starting dosage; caution is advised in patients with moderate or severe liver dysfunction. No adjustment to the starting dosage is needed in patients with mild liver dysfunction.

There are no data on the pharmacokinetics of sacituzumab govitecan in patients with severe renal dysfunction (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min); caution is recommended in these patients.